Moyer R R
Am Heart J. 1983 Nov;106(5 Pt 2):1250-3. doi: 10.1016/0002-8703(83)90184-9.
Data are presented on 22 hypertensive patients in an 18-week, double-blind comparison of trimazosin and methyldopa during which treatment with polythiazide was continued. Maximum daily doses of trimazosin and methyldopa were 800 and 2000 mg, respectively. Eight of nine patients receiving trimazosin and 8 of 12 receiving methyldopa had excellent or good overall responses. (One trimazosin patient was not evaluated for overall response.) Quantitative criteria of blood pressure response indicated that trimazosin was as effective as methyldopa. There were no clinically significant changes in results of Holter monitor recordings, ECGs, chest x-ray films, cardiopulmonary tests, or ophthalmoscopy. There were no abnormalities in laboratory tests of trimazosin patients. One patient receiving methyldopa had a positive Coombs' test. Significant side effects developed in two methyldopa patients-syncope in one patient and postural hypotension in the other. No significant side effects occurred in the patients taking trimazosin.
本文呈现了22例高血压患者在为期18周的曲马唑嗪与甲基多巴双盲对照试验中的数据，在此期间继续使用多噻嗪进行治疗。曲马唑嗪和甲基多巴的最大日剂量分别为800毫克和2000毫克。接受曲马唑嗪治疗的9例患者中有8例、接受甲基多巴治疗的12例患者中有8例获得了良好或极佳的总体疗效。（1例曲马唑嗪患者未评估总体疗效。）血压反应的定量标准表明，曲马唑嗪与甲基多巴疗效相当。动态心电图监测记录、心电图、胸部X光片、心肺检查或眼底检查结果均无临床显著变化。曲马唑嗪治疗患者的实验室检查未发现异常。1例接受甲基多巴治疗的患者库姆斯试验呈阳性。2例甲基多巴治疗患者出现了显著的副作用，1例患者出现晕厥，另1例出现体位性低血压。服用曲马唑嗪的患者未出现显著副作用。
